AHA Friday urged the U.S. District Court for the District of Columbia to deny the Department of Health and Human Services’ request to modify a court order requiring it to completely eliminate the remaining 19,802 Medicare appeals backlogged at the Administration Law Judge level. HHS now contends that it cannot fully comply with the order, stating that “it is unlikely that the backlog could be reduced completely to zero by the end of the fiscal year.”   
  
In a brief filed with the court, AHA said it would agree to a modest extension, but “the end goal must be the elimination of” the backlog. AHA also urged the court to require HHS to file monthly, rather than quarterly, status reports that include additional information on the remaining backlogged cases.  
  
The court in 2018 ruled in favor of the AHA and its member hospital plaintiffs in the case, requiring the HHS to eliminate the appeals backlog by fiscal year 2022. Congress also allocated HHS enough funds for 170 ALJ-led teams to adjudicate the hundreds of thousands of Medicare appeals that had piled up at the agency. 

Perspective
Public
Approximately 35 million Americans are enrolled in Medicare Advantage plans in 2026, and that number is expected to grow to about 45 million MA enrollees by…
Headline
The Centers for Medicare & Medicaid Services has released details on downloading its upcoming fiscal year 2025 Program for Evaluating Payment Patterns…
Headline
The Department of Health and Human Services Administration for Community Living has launched the first phase of its Health at Home Challenge, a competition to…
Headline
The AHA shared the following statement with the media in response to a report released May 7 by Families USA.   “This report is long on rhetoric and…
Headline
The AHA May 7 wrote to House and Senate lawmakers in support of the Medicare Advantage Improvement Act (H.R. 8375/S. 4384), bipartisan and bicameral…
Headline
The Centers for Medicare & Medicaid Services announced May 6 that it will provide access to certain glucagon-like peptide-1 (GLP-1) medications to eligible…